Targeted Therapeutics for Multiple Myeloma: The Arrival of a Risk-Stratified Approach

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-06-0620
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Vitamin A-Aldehyde Adducts: AMD Risk and Targeted Therapeutics

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2016English

Lipid Raft-Targeted Therapy in Multiple Myeloma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2010English

Targeted Therapeutics

Cell
BiochemistryGeneticsMolecular Biology
2011English

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Clinical Cancer Research
Cancer ResearchOncology
2015English

Novel Targeted Therapeutics for MEN2

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2018English

Design, Synthesis, and Biological Evaluation of Bone-Targeted Proteasome Inhibitors for Multiple Myeloma

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2013English

Socioeconomic Status and Risk of Multiple Myeloma.

Journal of Epidemiology and Community Health
EpidemiologyPublic HealthOccupational HealthEnvironmental
1985English

A High-Risk Signature for Patients With Multiple Myeloma Established From the Molecular Classification of Human Myeloma Cell Lines

Haematologica
Hematology
2010English

RNA-Targeted Therapeutics

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy